MODERN TREATMENT OF LYMPHOEDEMA II. THE BENZOPYRONES.
Identifieur interne : 001634 ( Istex/Corpus ); précédent : 001633; suivant : 001635MODERN TREATMENT OF LYMPHOEDEMA II. THE BENZOPYRONES.
Auteurs : John R. Casley-Smith ; Judith R. Casley-SmithSource :
- Australasian Journal of Dermatology [ 0004-8380 ] ; 1992-08.
Abstract
The benzo‐pyrones reduce all high‐protein oedemas, including lymphoedema and elephantiasis, by increasing the numbers of macrophages and their normal proteolysis. Thus they remove the excess protein, and thereby the oedema which is caused by it. They also remove the stimulus it provides for chronic inflammation and fibrosis, and its action as a culture medium for bacteria. Coumarin (5,6 benzo‐[alpha]‐pyrone, 56 BaP) and oxerutins (HR, O(β‐hydroxy‐ethyl)‐rutosides) have been used in many clinical trials on a variety of high‐protein oedemas. Four such trials are summarised here: on lymphoedema and elephantiasis (from many causes in Australia, and filaritic in India and China). The drugs reduced these much more slowly than adequate physical therapy, but they did reduce them. About half the excess volume was removed over six months in the Australian trials. In India and China similar rates were achieved with lymphoedema, but elephantiasis reduced at a slower rate. The benzo‐pyrones convert a slowly worsening condition into a slowly improving one. No compression garments are necessary. In addition, the drugs considerably reduce the number of attacks of secondary acute infection, reduce the deformities of elephantiasis and considerably improve the patients'comfort and mobility. They may be taken orally, or applied topically, have very low toxicities and only few, minor side‐effects. They are useful in many other forms of high‐protein oedema, and improve the results of physical therapy for lymphoedema.
Url:
DOI: 10.1111/j.1440-0960.1992.tb00082.x
Links to Exploration step
ISTEX:3092DB1E546F6631397FBF6085799AB2F142289CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">MODERN TREATMENT OF LYMPHOEDEMA II. THE BENZOPYRONES.</title><author><name sortKey="Casley Mith, John R" sort="Casley Mith, John R" uniqKey="Casley Mith J" first="John R." last="Casley-Smith">John R. Casley-Smith</name><affiliation><mods:affiliation>John R. Casley‐Smith D.Sc. MD(hc), The Henry Thomas Laboratory, University of Adelaide, Adelaide.</mods:affiliation></affiliation><affiliation><mods:affiliation>Address for correspondence: Dr J.R. Casley‐Smith, The Henry Thomas Laboratory, University of Adelaide. Box 498, Adelaide, 5001, South Australia.</mods:affiliation></affiliation></author><author><name sortKey="Casley Mith, Judith R" sort="Casley Mith, Judith R" uniqKey="Casley Mith J" first="Judith R." last="Casley-Smith">Judith R. Casley-Smith</name><affiliation><mods:affiliation>Judith R. Casley‐Smith PhD, The Henry Thomas Laboratory, University of Adelaide, Adelaide.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3092DB1E546F6631397FBF6085799AB2F142289C</idno><date when="1992" year="1992">1992</date><idno type="doi">10.1111/j.1440-0960.1992.tb00082.x</idno><idno type="url">https://api.istex.fr/document/3092DB1E546F6631397FBF6085799AB2F142289C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001634</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001634</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">MODERN TREATMENT OF LYMPHOEDEMA II. THE BENZOPYRONES.</title><author><name sortKey="Casley Mith, John R" sort="Casley Mith, John R" uniqKey="Casley Mith J" first="John R." last="Casley-Smith">John R. Casley-Smith</name><affiliation><mods:affiliation>John R. Casley‐Smith D.Sc. MD(hc), The Henry Thomas Laboratory, University of Adelaide, Adelaide.</mods:affiliation></affiliation><affiliation><mods:affiliation>Address for correspondence: Dr J.R. Casley‐Smith, The Henry Thomas Laboratory, University of Adelaide. Box 498, Adelaide, 5001, South Australia.</mods:affiliation></affiliation></author><author><name sortKey="Casley Mith, Judith R" sort="Casley Mith, Judith R" uniqKey="Casley Mith J" first="Judith R." last="Casley-Smith">Judith R. Casley-Smith</name><affiliation><mods:affiliation>Judith R. Casley‐Smith PhD, The Henry Thomas Laboratory, University of Adelaide, Adelaide.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Australasian Journal of Dermatology</title><title level="j" type="alt">AUSTRALASIAN JOURNAL DERMATOLOGY</title><idno type="ISSN">0004-8380</idno><idno type="eISSN">1440-0960</idno><imprint><biblScope unit="vol">33</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="69">69</biblScope><biblScope unit="page" to="74">74</biblScope><biblScope unit="page-count">6</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1992-08">1992-08</date></imprint><idno type="ISSN">0004-8380</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0004-8380</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The benzo‐pyrones reduce all high‐protein oedemas, including lymphoedema and elephantiasis, by increasing the numbers of macrophages and their normal proteolysis. Thus they remove the excess protein, and thereby the oedema which is caused by it. They also remove the stimulus it provides for chronic inflammation and fibrosis, and its action as a culture medium for bacteria. Coumarin (5,6 benzo‐[alpha]‐pyrone, 56 BaP) and oxerutins (HR, O(β‐hydroxy‐ethyl)‐rutosides) have been used in many clinical trials on a variety of high‐protein oedemas. Four such trials are summarised here: on lymphoedema and elephantiasis (from many causes in Australia, and filaritic in India and China). The drugs reduced these much more slowly than adequate physical therapy, but they did reduce them. About half the excess volume was removed over six months in the Australian trials. In India and China similar rates were achieved with lymphoedema, but elephantiasis reduced at a slower rate. The benzo‐pyrones convert a slowly worsening condition into a slowly improving one. No compression garments are necessary. In addition, the drugs considerably reduce the number of attacks of secondary acute infection, reduce the deformities of elephantiasis and considerably improve the patients'comfort and mobility. They may be taken orally, or applied topically, have very low toxicities and only few, minor side‐effects. They are useful in many other forms of high‐protein oedema, and improve the results of physical therapy for lymphoedema.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>lymphoedema</json:string><json:string>oedema</json:string><json:string>elephantiasis</json:string><json:string>placebo</json:string><json:string>coumarin</json:string><json:string>benzo</json:string><json:string>filaritic</json:string><json:string>macrophage</json:string><json:string>pyrone</json:string><json:string>benzopyrones</json:string><json:string>filaritic lymphoedema</json:string><json:string>active drug</json:string><json:string>modern treatment</json:string><json:string>inflammation</json:string><json:string>excess protein</json:string><json:string>chronic lymphoedema</json:string><json:string>skin temperature</json:string><json:string>compression garments</json:string><json:string>chronic inflammation</json:string><json:string>linear regression lines</json:string><json:string>lymphoedematous limbs</json:string><json:string>excess fibrosis</json:string><json:string>physical therapy</json:string><json:string>compression bandages</json:string><json:string>fewer attacks</json:string><json:string>normal proteolysis</json:string><json:string>australian patients</json:string><json:string>indian trial</json:string><json:string>lymphadenitis ulcers</json:string><json:string>bacterial infection</json:string><json:string>open symbols</json:string><json:string>topical presentations</json:string><json:string>limb</json:string></teeft></keywords><author><json:item><name>John R. Casley‐Smith</name><affiliations><json:string>John R. Casley‐Smith D.Sc. MD(hc), The Henry Thomas Laboratory, University of Adelaide, Adelaide.</json:string><json:string>Address for correspondence: Dr J.R. Casley‐Smith, The Henry Thomas Laboratory, University of Adelaide. Box 498, Adelaide, 5001, South Australia.</json:string></affiliations></json:item><json:item><name>Judith R. Casley‐Smith</name><affiliations><json:string>Judith R. Casley‐Smith PhD, The Henry Thomas Laboratory, University of Adelaide, Adelaide.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>lymphoedema</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>elephantiasis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>benzo‐pyrones</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>lymphatic</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>5,6 benzo‐α‐pyrone</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>56 BaP</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>coumarin</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>oxerutins</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>HR</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Paroven</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Venoruton</value></json:item></subject><articleId><json:string>AJD69</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>The benzo‐pyrones reduce all high‐protein oedemas, including lymphoedema and elephantiasis, by increasing the numbers of macrophages and their normal proteolysis. Thus they remove the excess protein, and thereby the oedema which is caused by it. They also remove the stimulus it provides for chronic inflammation and fibrosis, and its action as a culture medium for bacteria. Coumarin (5,6 benzo‐[alpha]‐pyrone, 56 BaP) and oxerutins (HR, O(β‐hydroxy‐ethyl)‐rutosides) have been used in many clinical trials on a variety of high‐protein oedemas. Four such trials are summarised here: on lymphoedema and elephantiasis (from many causes in Australia, and filaritic in India and China). The drugs reduced these much more slowly than adequate physical therapy, but they did reduce them. About half the excess volume was removed over six months in the Australian trials. In India and China similar rates were achieved with lymphoedema, but elephantiasis reduced at a slower rate. The benzo‐pyrones convert a slowly worsening condition into a slowly improving one. No compression garments are necessary. In addition, the drugs considerably reduce the number of attacks of secondary acute infection, reduce the deformities of elephantiasis and considerably improve the patients'comfort and mobility. They may be taken orally, or applied topically, have very low toxicities and only few, minor side‐effects. They are useful in many other forms of high‐protein oedema, and improve the results of physical therapy for lymphoedema.</abstract><qualityIndicators><score>6.179</score><pdfVersion>1.4</pdfVersion><pdfPageSize>467 x 671 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1520</abstractCharCount><pdfWordCount>2979</pdfWordCount><pdfCharCount>19493</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>225</abstractWordCount></qualityIndicators><title>MODERN TREATMENT OF LYMPHOEDEMA II. THE BENZOPYRONES.</title><genre><json:string>article</json:string></genre><host><title>Australasian Journal of Dermatology</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1440-0960</json:string></doi><issn><json:string>0004-8380</json:string></issn><eissn><json:string>1440-0960</json:string></eissn><publisherId><json:string>AJD</json:string></publisherId><volume>33</volume><issue>2</issue><pages><first>69</first><last>74</last><total>6</total></pages><genre><json:string>journal</json:string></genre></host><categories><wos><json:string>science</json:string><json:string>dermatology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>dermatology & venereal diseases</json:string></scienceMetrix><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string><json:string>ophtalmologie</json:string></inist></categories><publicationDate>1992</publicationDate><copyrightDate>1992</copyrightDate><doi><json:string>10.1111/j.1440-0960.1992.tb00082.x</json:string></doi><id>3092DB1E546F6631397FBF6085799AB2F142289C</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/3092DB1E546F6631397FBF6085799AB2F142289C/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/3092DB1E546F6631397FBF6085799AB2F142289C/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/3092DB1E546F6631397FBF6085799AB2F142289C/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">MODERN TREATMENT OF LYMPHOEDEMA II. THE BENZOPYRONES.</title></titleStmt><publicationStmt><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1992-08"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">MODERN TREATMENT OF LYMPHOEDEMA II. THE BENZOPYRONES.</title><author xml:id="author-0000" role="corresp"><persName><forename type="first">John R.</forename><surname>Casley‐Smith</surname></persName><affiliation>John R. Casley‐Smith D.Sc. MD(hc), The Henry Thomas Laboratory, University of Adelaide, Adelaide.</affiliation><affiliation>Address for correspondence: Dr J.R. Casley‐Smith, The Henry Thomas Laboratory, University of Adelaide. Box 498, Adelaide, 5001, South Australia.</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Judith R.</forename><surname>Casley‐Smith</surname></persName><affiliation>Judith R. Casley‐Smith PhD, The Henry Thomas Laboratory, University of Adelaide, Adelaide.</affiliation></author><idno type="istex">3092DB1E546F6631397FBF6085799AB2F142289C</idno><idno type="DOI">10.1111/j.1440-0960.1992.tb00082.x</idno><idno type="unit">AJD69</idno><idno type="toTypesetVersion">file:AJD.AJD69.pdf</idno></analytic><monogr><title level="j" type="main">Australasian Journal of Dermatology</title><title level="j" type="alt">AUSTRALASIAN JOURNAL DERMATOLOGY</title><idno type="pISSN">0004-8380</idno><idno type="eISSN">1440-0960</idno><idno type="book-DOI">10.1111/(ISSN)1440-0960</idno><idno type="book-part-DOI">10.1111/ajd.1992.33.issue-2</idno><idno type="product">AJD</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">33</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="69">69</biblScope><biblScope unit="page" to="74">74</biblScope><biblScope unit="page-count">6</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1992-08"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><abstract xml:lang="en" style="main"><head>S<hi rend="smallCaps">ummary</hi></head><p>The benzo‐pyrones reduce all high‐protein oedemas, including lymphoedema and elephantiasis, by increasing the numbers of macrophages and their normal proteolysis. Thus they remove the excess protein, and thereby the oedema which is caused by it. They also remove the stimulus it provides for chronic inflammation and fibrosis, and its action as a culture medium for bacteria. Coumarin (5,6 benzo‐[alpha]‐pyrone, 56 BaP) and oxerutins (HR, O(β‐hydroxy‐ethyl)‐rutosides) have been used in many clinical trials on a variety of high‐protein oedemas.</p><p>Four such trials are summarised here: on lymphoedema and elephantiasis (from many causes in Australia, and filaritic in India and China). The drugs reduced these much more slowly than adequate physical therapy, but they did reduce them. About half the excess volume was removed over six months in the Australian trials. In India and China similar rates were achieved with lymphoedema, but elephantiasis reduced at a slower rate. The benzo‐pyrones convert a slowly worsening condition into a slowly improving one. No compression garments are necessary. In addition, the drugs considerably reduce the number of attacks of secondary acute infection, reduce the deformities of elephantiasis and considerably improve the patients'comfort and mobility. They may be taken orally, or applied topically, have very low toxicities and only few, minor side‐effects. They are useful in many other forms of high‐protein oedema, and improve the results of physical therapy for lymphoedema.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="k1">lymphoedema</term><term xml:id="k2">elephantiasis</term><term xml:id="k3">benzo‐pyrones</term><term xml:id="k4">lymphatic</term><term xml:id="k5">5,6 benzo‐α‐pyrone</term><term xml:id="k6">56 BaP</term><term xml:id="k7">coumarin</term><term xml:id="k8">oxerutins</term><term xml:id="k9">HR</term><term xml:id="k10">Paroven</term><term xml:id="k11">Venoruton</term></keywords></textClass><langUsage><language ident="EN"></language></langUsage></profileDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/3092DB1E546F6631397FBF6085799AB2F142289C/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1440-0960</doi><issn type="print">0004-8380</issn><issn type="electronic">1440-0960</issn><idGroup><id type="product" value="AJD"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="AUSTRALASIAN JOURNAL DERMATOLOGY">Australasian Journal of Dermatology</title></titleGroup></publicationMeta><publicationMeta level="part" position="08002"><doi origin="wiley">10.1111/ajd.1992.33.issue-2</doi><numberingGroup><numbering type="journalVolume" number="33">33</numbering><numbering type="journalIssue" number="2">2</numbering></numberingGroup><coverDate startDate="1992-08">August 1992</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="0006900" status="forIssue"><doi origin="wiley">10.1111/j.1440-0960.1992.tb00082.x</doi><idGroup><id type="unit" value="AJD69"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><eventGroup><event type="firstOnline" date="2007-06-28"></event><event type="publishedOnlineFinalForm" date="2007-06-28"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-08"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-15"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="69">69</numbering><numbering type="pageLast" number="74">74</numbering></numberingGroup><correspondenceTo>Address for correspondence: Dr J.R. Casley‐Smith, The Henry Thomas Laboratory, University of Adelaide. Box 498, Adelaide, 5001, South Australia.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:AJD.AJD69.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="referenceTotal" number="9"></count><count type="linksCrossRef" number="3"></count></countGroup><titleGroup><title type="main">MODERN TREATMENT OF LYMPHOEDEMA II. THE BENZOPYRONES.</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1" corresponding="yes"><personName><givenNames>John R.</givenNames><familyName>Casley‐Smith</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a2"><personName><givenNames>Judith R.</givenNames><familyName>Casley‐Smith</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1"><unparsedAffiliation>John R. Casley‐Smith D.Sc. MD(hc), The Henry Thomas Laboratory, University of Adelaide, Adelaide.</unparsedAffiliation></affiliation><affiliation xml:id="a2"><unparsedAffiliation>Judith R. Casley‐Smith PhD, The Henry Thomas Laboratory, University of Adelaide, Adelaide.</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">lymphoedema</keyword><keyword xml:id="k2">elephantiasis</keyword><keyword xml:id="k3">benzo‐pyrones</keyword><keyword xml:id="k4">lymphatic</keyword><keyword xml:id="k5">5,6 benzo‐α‐pyrone</keyword><keyword xml:id="k6">56 BaP</keyword><keyword xml:id="k7">coumarin</keyword><keyword xml:id="k8">oxerutins</keyword><keyword xml:id="k9">HR</keyword><keyword xml:id="k10">Paroven</keyword><keyword xml:id="k11">Venoruton</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">S<sc>ummary</sc></title><p>The benzo‐pyrones reduce all high‐protein oedemas, including lymphoedema and elephantiasis, by increasing the numbers of macrophages and their normal proteolysis. Thus they remove the excess protein, and thereby the oedema which is caused by it. They also remove the stimulus it provides for chronic inflammation and fibrosis, and its action as a culture medium for bacteria. Coumarin (5,6 benzo‐[alpha]‐pyrone, 56 BaP) and oxerutins (HR, O(β‐hydroxy‐ethyl)‐rutosides) have been used in many clinical trials on a variety of high‐protein oedemas.</p><p>Four such trials are summarised here: on lymphoedema and elephantiasis (from many causes in Australia, and filaritic in India and China). The drugs reduced these much more slowly than adequate physical therapy, but they did reduce them. About half the excess volume was removed over six months in the Australian trials. In India and China similar rates were achieved with lymphoedema, but elephantiasis reduced at a slower rate. The benzo‐pyrones convert a slowly worsening condition into a slowly improving one. No compression garments are necessary. In addition, the drugs considerably reduce the number of attacks of secondary acute infection, reduce the deformities of elephantiasis and considerably improve the patients'comfort and mobility. They may be taken orally, or applied topically, have very low toxicities and only few, minor side‐effects. They are useful in many other forms of high‐protein oedema, and improve the results of physical therapy for lymphoedema.</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="n-fnt-1" numbered="no"><p>This paper was presented at the Scientific Meeting of the Australasian College of Dermatologists, Perth, May 1992.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>MODERN TREATMENT OF LYMPHOEDEMA II. THE BENZOPYRONES.</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>MODERN TREATMENT OF LYMPHOEDEMA II. THE BENZOPYRONES.</title></titleInfo><name type="personal"><namePart type="given">John R.</namePart><namePart type="family">Casley‐Smith</namePart><affiliation>John R. Casley‐Smith D.Sc. MD(hc), The Henry Thomas Laboratory, University of Adelaide, Adelaide.</affiliation><affiliation>Address for correspondence: Dr J.R. Casley‐Smith, The Henry Thomas Laboratory, University of Adelaide. Box 498, Adelaide, 5001, South Australia.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Judith R.</namePart><namePart type="family">Casley‐Smith</namePart><affiliation>Judith R. Casley‐Smith PhD, The Henry Thomas Laboratory, University of Adelaide, Adelaide.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">1992-08</dateIssued><copyrightDate encoding="w3cdtf">1992</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">9</extent></physicalDescription><abstract lang="en">The benzo‐pyrones reduce all high‐protein oedemas, including lymphoedema and elephantiasis, by increasing the numbers of macrophages and their normal proteolysis. Thus they remove the excess protein, and thereby the oedema which is caused by it. They also remove the stimulus it provides for chronic inflammation and fibrosis, and its action as a culture medium for bacteria. Coumarin (5,6 benzo‐[alpha]‐pyrone, 56 BaP) and oxerutins (HR, O(β‐hydroxy‐ethyl)‐rutosides) have been used in many clinical trials on a variety of high‐protein oedemas. Four such trials are summarised here: on lymphoedema and elephantiasis (from many causes in Australia, and filaritic in India and China). The drugs reduced these much more slowly than adequate physical therapy, but they did reduce them. About half the excess volume was removed over six months in the Australian trials. In India and China similar rates were achieved with lymphoedema, but elephantiasis reduced at a slower rate. The benzo‐pyrones convert a slowly worsening condition into a slowly improving one. No compression garments are necessary. In addition, the drugs considerably reduce the number of attacks of secondary acute infection, reduce the deformities of elephantiasis and considerably improve the patients'comfort and mobility. They may be taken orally, or applied topically, have very low toxicities and only few, minor side‐effects. They are useful in many other forms of high‐protein oedema, and improve the results of physical therapy for lymphoedema.</abstract><subject lang="en"><genre>keywords</genre><topic>lymphoedema</topic><topic>elephantiasis</topic><topic>benzo‐pyrones</topic><topic>lymphatic</topic><topic>5,6 benzo‐α‐pyrone</topic><topic>56 BaP</topic><topic>coumarin</topic><topic>oxerutins</topic><topic>HR</topic><topic>Paroven</topic><topic>Venoruton</topic></subject><relatedItem type="host"><titleInfo><title>Australasian Journal of Dermatology</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">0004-8380</identifier><identifier type="eISSN">1440-0960</identifier><identifier type="DOI">10.1111/(ISSN)1440-0960</identifier><identifier type="PublisherID">AJD</identifier><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>69</start><end>74</end><total>6</total></extent></part></relatedItem><identifier type="istex">3092DB1E546F6631397FBF6085799AB2F142289C</identifier><identifier type="DOI">10.1111/j.1440-0960.1992.tb00082.x</identifier><identifier type="ArticleID">AJD69</identifier><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001634 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001634 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:3092DB1E546F6631397FBF6085799AB2F142289C
|texte= MODERN TREATMENT OF LYMPHOEDEMA II. THE BENZOPYRONES.
}}
| This area was generated with Dilib version V0.6.31. |  |